References
1. Perlman S, Netland J. Coronaviruses post-SARS: update on replication
and pathogenesis. Nat Rev Microbiol 2009;7:439-50.
2. https://www.worldometers.info/coronavirus/ Date last accessed:
09.02.2021
3. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by
novel coronavirus from Wuhan: an analysis based on decade-long
structural studies of SARS. J Virol 2020;94:e00127-20.
4. Rodriguez GE, Shin BC, Abernathy RS, Kendig EL Jr. Serum
angiotensin-converting enzyme activity in normal children and in those
with sarcoidosis. J Pediatr 1981;99:68–72.
5. Bunyavanich S, Do A, Vicencio A. Nasal Gene Expression of
Angiotensin-Converting Enzyme 2 in Children and Adults. JAMA
2020;323:2427-2429.
6. Guo CX, He L, Yin JY, et al. Epidemiological and clinical features of
pediatric COVID-19. BMC Med 2020;18:250.
7. Wu Z, McGoogan JM. Characteristics of and important lessons from the
Coronavirus Disease 2019 (COVID-19) Outbreak in China: summary of a
report of 72 314 cases from the Chinese Center for Disease Control and
prevention. JAMA 2020;323:1239-1242.
8. Kuba K, Imai Y, Penninger JM. Angiotensin-converting enzyme 2 in lung
diseases. Curr Opin Pharmacol 2006;6:271-6.
9. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F.
An insertion/deletion polymorphism in the angiotensin I-converting
enzyme gene accounting for half the variance of serum enzyme levels. J
Clin Invest 1990;86:1343-6.
10. Leung JM, Yang CX, Tam A, et al. ACE-2 Expression in the Small
Airway Epithelia of Smokers and COPD Patients: Implications
for COVID-19. Eur Respir J 2020;55:2000688.
11. Smith JC, Sausville EL, Girish V, et al. Cigarette smoke exposure
and inflammatory signaling increase the expression of the SARS‐CoV‐2
receptor ACE2 in the respiratory tract. Dev Cell 2020;53: 514–529.e3.
12. Chen YY, Zhang P, Zhou XM, et al. Relationship between genetic
variants of ACE2 gene and circulating levels of ACE2 and its
metabolites. J Clin Pharm Ther 2018;43:189-195.
13. Liu D, Chen Y, Zhang P, et al. Association between circulating
levels of ACE2-Ang-(1-7)-MAS axis and ACE2 gene polymorphisms in
hypertensive patients. Medicine (Baltimore) 2016;95:e3876.
14. Kramkowski K, Mogielnicki A, Buczko W. The physiological
significance of the alternative pathways of angiotensin II production. J
Physiol Pharmacol 2006;57:529–539.
15. Huang C, Wang Y, Li X, et al. Clinical features of patients infected
with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
16. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated
with a new coronavirus of probable bat origin. Nature 2020;579:270-273.
17. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus
Disease 2019 in China. N Engl J Med 2020;382:1708-1720.
18. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan,
China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med
2020;382:1199-1207.
19. Delanghe JR, Speeckaert MM, De Buyzere ML. The host’s
angiotensin-converting enzyme polymorphism may explain epidemiological
findings in COVID-19 infections. Clin Chim Acta 2020;505:192-193.
20. Saadat M. No significant correlation between ACE Ins/Del genetic
polymorphism and COVID-19 infection. Clin Chem Lab Med
2020;58:1127-1128.
21. Pati A, Mahto H, Padhi S, Panda AK. ACE deletion allele is
associated with susceptibility to SARS-CoV-2 infection and mortality
rate: An epidemiological study in the Asian population. Clin Chim Acta
2020;510:455-458.
22. Hatami N, Ahi S, Sadeghinikoo A, et al. Worldwide ACE (I/D)
polymorphism may affect COVID-19 recovery rate: an ecological
meta-regression. Endocrine 2020;68:479-484.
23. Novelli A, Biancolella M, Borgiani P, et al. Analysis of ACE2
genetic variants in 131 Italian SARS-CoV-2-positive patients. Hum
Genomics 2020;14:29.
24. Gómez J, Albaiceta GM, García-Clemente M, et al.
Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19
outcome. Gene 2020;762:145102.
25. Li Y, Li H, Zhou L. EZH2-mediated H3K27me3 inhibits ACE2 expression.
Biochem Biophys Res Commun 2020;526:947-952.
26. Lambert DW, Clarke NE, Hooper NM, Turner AJ. Calmodulin interacts
with angiotensin-converting enzyme-2 (ACE2) and inhibits shedding of its
ectodomain. FEBS Lett 2008;582:385-90.
27. Saponaro F, Rutigliano G, Sestito S, et al. ACE2 in the Era of
SARS-CoV-2: Controversies and Novel Perspectives. Front Mol Biosci
2020;7:588618.
28. Wang Y, Zhang L, Sang L, et al. Kinetics of viral load and antibody
response in relation to COVID-19 severity. J Clin Invest
2020;130:5235-5244.
29. Liu Y, Yan LM, Wan L, et al. Viral dynamics in mild and severe cases
of COVID-19. Lancet Infect Dis 2020;20:656-657.
30. Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S.
Cytokine storm in COVID-19: pathogenesis and overview of
anti-inflammatory agents used in treatment. Clin Rheumatol
2020;39:2085-2094.
31. Liu Y, Liao W, Wan L, Xiang T, Zhang W. Correlation Between Relative
Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in
Patients with COVID-19. Viral Immunol 2020 Apr 10. DOI:
10.1089/vim.2020.0062 [Epub ahead of print].
32. Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral
load in a community outbreak of coronavirus-associated SARS pneumonia: a
prospective study. Lancet 2003;361:1767-72.